Status:
TERMINATED
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
Lead Sponsor:
Northwell Health
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
19-79 years
Phase:
NA
Brief Summary
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart diseas...
Detailed Description
Background Compared with the general population, patients with schizophrenia have an increased risk of death from atherosclerotic cardiovascular diseases (ASCVD) that reflect coronary heart disease, ...
Eligibility Criteria
Inclusion
- patients with schizophrenia treated with clozapine; age 19-79
Exclusion
- pregnant women, personal history of/or comorbid eating disorders
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00794963
Start Date
November 1 2008
End Date
May 1 2010
Last Update
April 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zucker Hillside Hospital
Glen Oaks, New York, United States, 11004